[A long-surviving patient with Stage IV breast cancer with no recurrence after combined therapy of medroxy progesterone acetate (MPA) and intra-arterial infusion chemotherapy].
Yamada
Takeshi
T
Shinsapporo Breast Clinic.
Yuyama
Yuichi
Y
Okazaki
Yutaka
Y
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D009367:Neoplasm Staging; D017741:Survivors; D013629:Tamoxifen / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D005467:Floxuridine; D013629:Tamoxifen; D015251:Epirubicin; D017258:Medroxyprogesterone Acetate; C025034:doxifluridine